Article
Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil.
Malaria journal - 28 Feb 2014
Aguiar Anna Caroline C, Pereira Dhelio B, Amaral Nayra S, De Marco Luiz, Krettli Antoniana U
Abstract excerpt
BACKGROUND: Chloroquine (CQ), a cost effective antimalarial drug with a relatively good safety profile and therapeutic index, is no longer used by itself to treat patients with Plasmodium falciparum due to CQ-resistant strains. P. vivax, representing over 90% of malaria cases in Brazil, despite reported resistance, is treated with CQ as well as with primaquine to block malaria transmission and avoid late P. vivax...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
